SvedbergOpen
DISSEMINATION OF KNOWLEDGE

International Journal of Artificial Intelligence and Machine Learning

Publisher's Home Page: https://www.svedbergopen.com/

Research Paper Open Access

# An AI-Driven Mathematical Modeling Framework for Personalized Cancer Therapy Using Genomic Networks and Deep Learning

[1]Dr. R. Uma, [2]Dr. S. Sreedevi, [3]Dr. V. Kamalakannan, [4]Dr Jayasundar S, [5]Rupa Rani Dewangan, [6]Dr. Dhiraj Sharma, [7]Senthil Prabhu Sivasamy, [8]Dr. S. Meher Taj

[1]Associate Professor, Department of Mathematics, Sree Saraswathi Thyagaraja College, Pollachi, Coimbatore, Tamilnadu, India, 642107. E- mail : ramumaraj@gmail.com
[2]Associate Professor, Department of Management Studies, Sri Venkateswara College of Engineering, Tirupati, ANDHRAPRADESH, India, 516501. E- mail: sreedevireddy2@gmail.com
[3]Assistant Professor, Department of Mathematics, Panimalar Engineering college, Chennai, Tamil Nadu, India, 600 123.
E-mail: mail2kamalakannan@gmail.com
[4]Professor & Head, Department of Computer science and Engineering, A.K.T Memorial College of Engineering and Technology, Kallakurichi, Tamil Nadu, India, 606213. E-mail: chisundar123@gmail.com, Orcid: 0000-0002-6456-9277
[5]Assistant Professor, Department of Applied Mathematics, Bhilai Institute of Technology Durg, Chhattisgarh India,491001.
E-mail: ruparani.dewangan@bitdurg.ac.in
[6]Assistant Professor, University School of Law, Department of University of School Law,Guru Kashi University, Talwandi Sabo, Bathinda, Punjab, India,151302. E-mail: ds6057479@gmail.com
[7]Professor, Department of Microbiology, Dr. N.G.P Arts and Science College, Coimbatore, Tamil Nadu, India,641 048.
E-mail: sepisp@gmail.com
[8]Associate Professor, Department of Mathematics, AMET Deemed to be University, ECR, Kanathur, Chennai_603112.
E-mail: mehertaj.s@ametuniv.ac.in
*Corresponding Author: Dr. S. Sreedevi, E- mail: sreedevireddy2@gmail.com

**Abstract**
Cancer is a highly heterogeneous disease characterized by complex genetic alterations, molecular interactions, signaling pathways, and dynamic tumor evolution, which significantly influence disease progression and therapeutic response. Conventional treatment strategies often rely on generalized clinical and pathological characteristics and may not adequately capture patient-specific molecular differences. Therefore, there is a growing need for computational approaches capable of supporting personalized cancer-treatment decisions. This study proposes an artificial intelligence (AI)-driven framework that integrates mathematical modeling of genomic networks with deep learning for personalized cancer therapy. Patient-specific genomic and clinical information, including gene expression profiles, somatic mutations, copy-number alterations, and other molecular characteristics, is utilized to construct individualized genomic networks. Mathematical modeling is employed to quantify gene relationships, molecular interactions, and pathway structures and to derive biologically meaningful network-based features. These features are subsequently analyzed using deep learning techniques, particularly Graph Neural Networks (GNNs), to capture complex relationships between genomic characteristics and therapeutic outcomes. Multi-omics data integration is incorporated to provide a comprehensive representation of tumor biology and improve predictive performance. Furthermore, Explainable Artificial Intelligence (XAI) techniques are employed to identify key genes, signaling pathways, and network interactions contributing to treatment-response predictions. The proposed framework aims to predict treatment response and drug sensitivity while simultaneously providing interpretable biological insights. By integrating mathematical modeling, genomic network analysis, multi-omics data, deep learning, and explainable AI, this framework establishes a computational foundation for precision oncology and supports personalized cancer-treatment decision-making.

**Keywords:** Personalized Cancer Therapy, Precision Oncology, Cancer Genomics, Mathematical Modeling, Genomic Networks, Deep Learning, Graph Neural Networks, Multi-Omics, Drug Response Prediction, Explainable AI.

## 1. Introduction

Cancer is a complex and heterogeneous disease characterized by genetic alterations, abnormal cellular signaling, uncontrolled proliferation, and interactions among multiple biological systems. The molecular characteristics of tumors can vary considerably between patients, even when they have the same cancer type. Such differences can influence disease progression, therapeutic response, and the development of treatment resistance [1]. Modern cancer genomics has therefore shifted research toward understanding tumors at the molecular and systems level rather than relying only on conventional clinical classifications. Large-scale genomic initiatives have generated extensive molecular datasets containing information about mutations, gene expression, copy-number alterations, DNA methylation, and other molecular characteristics [2]. These datasets provide an important foundation for precision oncology. The Cancer Cell Line Encyclopedia and the Genomics of Drug Sensitivity in Cancer resources have further demonstrated the

potential of linking molecular characteristics with anticancer drug sensitivity [3,4]. Large pharmacogenomic studies have also shown that genomic alterations can be associated with differential sensitivity to therapeutic compounds [5].

However, genomic information is high-dimensional and highly interconnected. Individual genes rarely function independently; instead, they participate in regulatory networks, protein-protein interactions, signaling pathways, and cellular processes. Consequently, analyzing individual genes separately may not adequately capture the biological mechanisms underlying cancer progression or treatment response. Gene-set and pathway-based methods have demonstrated the importance of analyzing groups of functionally related genes [6,7]. Biological interaction databases such as STRING and pathway resources such as KEGG provide valuable prior knowledge for constructing genomic networks [8,9].




**Figure 1.** Overview of the proposed AI-driven framework for personalized cancer therapy. The framework integrates multi-omics data, constructs patient-specific genomic networks, applies mathematical modeling to extract biologically meaningful features, uses Graph Neural Networks to learn complex patterns, and generates treatment-response predictions with explainable insights.

Network-based approaches are particularly relevant to precision oncology because cancer-associated alterations may affect interconnected molecular pathways rather than isolated genes. Zhang et al. demonstrated the potential of network-based machine learning and graph-theoretical approaches for precision oncology, emphasizing that cancer can often be better understood through altered pathways and molecular networks [10].

Mathematical modeling provides another approach for understanding complex cancer biology. Mathematical and computational models have been applied to tumor dynamics, treatment response, drug resistance, signaling networks, and cancer evolution [11,12]. Such models can represent biological processes using differential equations, stochastic models, network models, and other mathematical approaches. Mathematical modeling can therefore complement genomic analysis by providing a quantitative representation of molecular interactions and tumor behavior.

The emergence of deep learning has created new opportunities for analyzing high-dimensional biological data. Deep learning models can learn hierarchical and nonlinear representations from complex datasets [13]. Graph-based deep learning is particularly promising for genomic applications because genomic information can naturally be represented as a graph in which genes or proteins form nodes and their biological relationships form edges. Graph Convolutional Networks and Graph Attention Networks provide mechanisms for learning from both node characteristics and graph structure [14,15].

Deep learning has already been investigated for cancer drug-response prediction. Multi-omics deep learning approaches such as MOLI have demonstrated the value of combining mutation, copy-number, and gene-expression information for drug-response prediction [16]. Deep learning has also been used to predict drug efficacy from transcriptional profiles [17]. Attention-based models have further demonstrated the possibility of integrating molecular information and protein-interaction networks while improving interpretability [18].

Despite these advances, a major challenge remains the development of models that combine patient-specific genomic networks, mathematical modeling, deep learning, and interpretability within a unified framework. The proposed study addresses this research gap by developing an AI-driven mathematical modeling framework for personalized cancer therapy.

## 2. Problem Statement

Cancer treatment response varies substantially among patients because of differences in genomic alterations, molecular pathways, tumor heterogeneity, and treatment resistance. Existing computational approaches often analyze genomic features individually or use conventional machine-learning methods that may not fully capture the complex relationships between interacting molecular components.

Deep learning can identify complex nonlinear patterns, but many deep-learning models operate as black boxes and provide limited biological explanations for their predictions. Interpretability is particularly important in precision oncology because clinicians and researchers need to understand which genomic characteristics contribute to treatment recommendations [19].
Therefore, there is a need for an integrated computational framework that can:

- represent patient-specific genomic interactions;
- mathematically model molecular networks;
- integrate multiple genomic and clinical data types;
- predict treatment response and drug sensitivity;
- identify potential resistance mechanisms; and
- provide interpretable explanations for AI predictions.

The proposed study addresses these challenges through the integration of genomic network modeling, mathematical modeling, graph-based deep learning, and Explainable AI.

## 3. Literature Review

Cancer genomics has transformed precision oncology by providing molecular information that can be used to characterize individual tumors. The Cancer Genome Atlas established a large-scale framework for studying molecular alterations across multiple cancer types [2]. Pharmacogenomic resources such as GDSC and CCLE subsequently enabled researchers to investigate associations between molecular features and anticancer drug response [3,4]. The large-scale analysis by Iorio et al. demonstrated how genomic alterations can be connected with drug sensitivity across cancer cell lines [5]. Cancer-associated genes function within interconnected biological systems. Gene-set enrichment analysis provides a method for identifying biological processes associated with genomic profiles [6], while the Hallmark gene sets provide curated representations of important biological states and processes [7]. Protein-interaction networks from resources such as STRING can provide additional biological relationships for network construction [8]. KEGG provides pathway-level information that can support the interpretation of genomic alterations [9]. Network-based machine learning has therefore become an important research direction in precision oncology. Network approaches can identify disease modules, functional interactions, and pathway-level patterns that may not be detected by single-gene analysis [10]. Mathematical modeling has been widely applied to cancer growth, treatment response, resistance evolution, and tumor dynamics. Mathematical models can represent tumor growth using deterministic or stochastic approaches and can incorporate treatment effects and resistance evolution [11,12]. Such models can provide a quantitative framework for studying cancer dynamics and may support treatment optimization. Mathematical modeling of drug resistance has also incorporated signaling networks, gene interactions, and multi-omics information. These approaches demonstrate the potential of combining mechanistic models with data-driven prediction methods [11,12]. Recent reviews continue to identify mathematical modeling and bioinformatics as important approaches for understanding treatment resistance and designing therapy strategies [20].

Deep learning enables computational systems to learn multiple levels of representation from complex datasets [13]. Its application to genomics has increased because of the growing availability of high-dimensional molecular datasets. Deep learning can identify nonlinear relationships between genomic features and biological outcomes that may be difficult to capture using traditional statistical models. Graph Neural Networks extend deep learning to graph-structured data. Graph Convolutional Networks learn node representations by aggregating information from neighboring nodes [14]. GraphSAGE introduced an inductive approach for generating node representations using local neighborhood information [15], while Graph Attention Networks introduced attention mechanisms that allow different importance to be assigned to neighboring nodes [21]. These characteristics make GNNs particularly suitable for genomic networks because genes, proteins, and pathways can be naturally represented as interconnected graph structures. Cancer biology is influenced by multiple molecular layers. Multi-omics integration can therefore provide a more comprehensive representation of tumor biology. Hasin et al. discussed the importance of integrating different omics technologies for disease research [22], while Argelaguet et al. proposed MOFA as a framework for integrating multi-omics datasets [23]. MOLI demonstrated the potential of combining somatic mutations, copy-number alterations, and gene-expression data using deep neural networks for drug-response prediction [16]. This provides a strong basis for incorporating multi-omics information into the proposed .Deep-learning methods have increasingly been applied to cancer drug-response prediction. Zhu et al. demonstrated that transcriptional profiles can be used with deep learning to predict drug efficacy [17]. Oskooei et al. developed PaccMann, an attention-based approach for predicting anticancer compound sensitivity using molecular and biological information [24]. Manica et al. further investigated explainable anticancer compound sensitivity prediction using multimodal attention-based architectures and protein-protein interaction information [18]. Recent research has moved toward graph-based and multi-omics architectures. GraphTCDR uses heterogeneous graph neural networks and multi-omics information for

cancer drug-response prediction [25], while other recent GNN approaches have investigated multi-task learning and heterogeneous network structures [26].

Accuracy alone is not sufficient for medical AI. Models should provide information that allows researchers and clinicians to understand their predictions. Explainable AI methods can identify important input features and relationships contributing to model outputs. Gimeno et al. reviewed interpretability in precision oncology and emphasized that the ability to understand model decisions is essential for trustworthy clinical implementation [19]. Attention-based approaches have also demonstrated potential for improving interpretability in anticancer drug-response prediction [18]. SHAP and LIME provide widely used model-interpretation approaches that can be incorporated into biomedical AI systems [27,28].Recent work demonstrates an increasing convergence between machine learning, genomics, graph learning, and precision oncology. A 2026 review in *Nature Reviews Cancer* describes the convergence of machine learning and genomics as an important development for precision cancer medicine [29]. A recent *npj Precision Oncology* review similarly highlights the expanding role of AI across oncology, including personalized treatment [30]. Recent graph-based studies have also demonstrated strong potential for multi-omics drug-response prediction. For example, Graph TCDR constructs heterogeneous networks integrating multi-omics and drug information [25], while MOGA uses graph-based multi-modal integration for drug-response prediction and reports improved generalization to clinical datasets [31].




**Figure 2.** Workflow for constructing patient-specific genomic networks and extracting mathematical modeling–based features. Prior-knowledge networks are integrated with patient molecular alterations to build personalized networks, which are then analyzed using mathematical models and network analysis to generate informative features.

Indhumathi (2026) examined the mathematical foundations of Explainable Artificial Intelligence (XAI), focusing on linear algebra, probability theory, optimization, information theory, graph theory, Shapley values, and causal inference. The study emphasized that mathematical principles play an important role in developing transparent and trustworthy AI systems. This work is particularly relevant to the proposed cancer-therapy framework because explainability is required to identify the genomic features and molecular pathways influencing treatment-response predictions [39]. Balraj and Karunanithi (2026) investigated Explainable Artificial Intelligence in decision-critical systems, emphasizing transparency, accountability, ethical considerations, and trustworthy AI. The authors highlighted the limitations of black-box deep-learning systems and the importance of interpretable decision support, particularly in sensitive areas such as healthcare. This study supports the proposed research by emphasizing the need for explainable AI when developing AI-assisted personalized cancer-treatment systems [40].
Kanimozhi (2026) reviewed adaptive computational models for intelligent data-driven decision systems in complex and uncertain environments. The study discussed probabilistic models, reinforcement learning, fuzzy logic, ensemble learning, hybrid models, and uncertainty quantification. The findings are relevant to personalized cancer therapy because patient genomic information and treatment responses are complex and uncertain, requiring adaptive and reliable computational approaches [41]. Pradeepa et al. (2026) examined the integration of Artificial Intelligence and Internet of Things technologies for intelligent and adaptive decision-making. The study emphasized secure, transparent, interoperable, and human-centered AI systems. Although the research focuses on smart-city applications, its emphasis on integrated AI architectures and intelligent decision support provides methodological relevance to the development of AI-based healthcare systems [42]. Anantharaman and Vishnupriya (2026) studied graph-theoretic models for network optimization, covering shortest-path algorithms, network flows, centrality, spectral graph theory, complex networks, and multilayer networks. The study emphasized that graph theory provides a mathematical framework for representing structural dependencies and relationships within complex systems. This is directly relevant to the proposed research because genes can be represented as nodes and their biological interactions as edges, forming a genomic network suitable for graph-based deep learning [43]. Savitha and Kavinkumar (2026) investigated the application of Artificial Intelligence for feedback and

data-driven learning, emphasizing supervised use of AI, responsible implementation, and the importance of human oversight. Although the application area is education, the study reinforces the broader principle that AI systems should support rather than completely replace human decision-making. This principle is applicable to AI-assisted cancer treatment, where computational predictions should support clinical expertise rather than replace medical professionals [44]. Moulieswaran et al. (2026) examined an AI-powered framework emphasizing personalization, adaptive feedback, responsible AI use, and human-centered decision-making. The study highlighted concerns including bias, privacy, reliability, and overdependence on AI systems. These considerations are relevant to personalized cancer therapy because genomic data are highly sensitive and AI predictions require appropriate validation and human interpretation [45].

**4. Research Gap**

The literature demonstrates substantial progress in cancer genomics, mathematical modeling, deep learning, graph neural networks, and drug-response prediction. However, several limitations remain.

First, many approaches focus primarily on genomic features without explicitly modeling patient-specific network relationships. Second, mathematical models and deep-learning models are often developed independently rather than as a unified framework. Third, multi-omics approaches may improve predictive performance but can increase dimensionality and computational complexity. Fourth, the clinical interpretability of deep-learning predictions remains a major challenge [19].

Therefore, a research gap exists in developing a unified framework that integrates:

*Patient Genomic Data → Genomic Network → Mathematical Modeling → Graph Deep Learning → Treatment Response Prediction → Explainable AI*

The proposed research addresses this gap.

**5. Contribution of the Study**

The proposed study is expected to make the following contributions:

1. Development of a patient-specific genomic network for cancer analysis.
2. Integration of mathematical modeling and deep learning.
3. Prediction of individual treatment response and drug sensitivity.
4. Identification of important genes and molecular pathways.
5. Detection of potential drug-resistance patterns.
6. Application of Explainable AI to improve model transparency.
7. Development of a computational framework supporting personalized cancer therapy.

## 6. Proposed Research Framework

The proposed research framework integrates genomic, mathematical, and artificial intelligence techniques into a unified system.

**Input Layer**

Patient-specific genomic and clinical information will be collected. The proposed input may include:

- Gene-expression profiles
- Somatic mutations
- Copy-number alterations
- DNA methylation
- Clinical characteristics
- Drug-response information
- Molecular pathway information

Large cancer resources such as TCGA, CCLE, and GDSC provide examples of datasets that can support such computational research [2–5].

**Data Preprocessing**

The collected data will undergo quality control, normalization, missing-value handling, feature selection, and dimensionality reduction where appropriate.

**Genomic Network Construction**

Genes or molecular components will be represented as nodes, while biological relationships will be represented as edges.

The patient-specific network can be represented as:

$$\mathbf{G_p = (V, E_p, W_p)}$$

where:

- $\mathbf{V}$ = genomic entities,
- $\mathbf{E_p}$ = patient-specific relationships,

• $\mathbf{W_p}$ = interaction weights.
Prior biological knowledge from protein-interaction and pathway databases can be incorporated into network construction [8,9].

**Mathematical Modeling**
The proposed framework represents each patient's genomic information as a weighted genomic network:

$$G = (V, E, W)$$

where $V$represents genes, $E$represents gene interactions, and $W$represents interaction strengths.
Patient-specific multi-omics data are represented by:

$$X = [E, M, C, O]$$

where $E$is gene expression, $M$is mutation data, $C$is copy-number alteration, and $O$represents other omics data.
The genomic network is modeled using the Laplacian matrix:

$$L = D - W$$

where $D$is the degree matrix. A Graph Neural Network (GNN) then learns the complex relationships between genomic features and treatment response:

$$H^{(l+1)} = \sigma\left(\hat{D}^{-1/2}\hat{A}\hat{D}^{-1/2}H^{(l)}W^{(l)}\right)$$

Finally, the optimal treatment is selected by maximizing predicted response while minimizing toxicity and resistance:

$$T^* = \arg\max_T \left[R(T) - \lambda_1 \, Toxicity(T) - \lambda_2 \, Resistance(T)\right]$$

Thus, the model integrates **genomic networks, mathematical modeling, GNNs, and optimization** to support personalized cancer therapy.
Mathematical models will be used to characterize the structure and behavior of the genomic network. Network-based features such as connectivity, centrality, pathway activity, and interaction strength can be extracted.
Dynamic or mechanistic models may also be investigated to represent treatment response and resistance evolution [11,12].

**7. Proposed System**
The proposed system consists of the following sequential stages:
*Patient Genomic and Clinical Data*
↓
*Data Preprocessing and Feature Selection*
↓
*Patient-Specific Genomic Network Construction*
↓
*Mathematical Modeling of Gene Interactions*
↓
*Multi-Omics Feature Integration*
↓
*Graph Neural Network / Deep Learning*
↓
*Drug Sensitivity and Treatment Response Prediction*
↓
*Explainable AI*
↓
*Personalized Cancer Therapy Support*
The system is designed to combine molecular information with network relationships rather than treating genes as isolated variables.

**Proposed System**
The proposed system integrates **multi-omics data, mathematical genomic-network modeling, Graph Neural Networks (GNNs), and Explainable AI (XAI)** to predict personalized cancer treatment.

| Patient Data → Multi-Omics Integration → Genomic Network → Mathematical Modeling → GNN → Treatment Prediction → XAI |
|---|

**Main Components**

1. **Patient Data Collection**

Gene expression, mutations, copy-number alterations, and clinical information are collected.

2. **Multi-Omics Integration**

Different molecular data types are combined to generate a comprehensive patient profile.

3. **Genomic Network Construction**

Genes are represented as nodes and their biological interactions as weighted edges.

4. **Mathematical Modeling**

Graph theory, matrix analysis, network centrality, and tumor-growth models are applied to identify important genomic patterns.

5. **GNN-Based Prediction**

GNN learns complex relationships between genomic features and treatment response.

6. **Drug Response Prediction**

The model predicts the effectiveness and sensitivity of candidate therapies for each patient.

7. **Personalized Treatment Selection**

The treatment with the highest predicted benefit and lowest toxicity/resistance risk is selected.

**Explainable AI**

XAI identifies the **key genes, pathways, and genomic interactions** responsible for the treatment recommendation.

Mathematical models will be developed to quantify molecular interactions and network behavior. Depending on the cancer type and available data, deterministic, stochastic, differential-equation, or network-based models can be investigated [11,12].

## 9. Discussion

The proposed framework integrates several complementary computational approaches for personalized cancer therapy. Genomic data provide detailed molecular information, while network modeling captures relationships between biological components. Mathematical modeling can provide a quantitative representation of these interactions, and deep learning can learn complex nonlinear relationships from the resulting network structures.

The use of GNNs is particularly appropriate because genomic systems can naturally be represented as graphs. GCN and GAT architectures can learn from both node-level molecular characteristics and neighborhood relationships [14,21]. Recent studies have demonstrated the potential of heterogeneous graph and multi-omics approaches for cancer drug-response prediction [25,26,31].

The integration of multiple omics layers may further improve biological representation. MOLI demonstrated that combining mutation, copy-number, and gene-expression data can improve drug-response prediction compared with certain single-omics approaches [16]. Similar multi-omics integration is therefore proposed in the present framework.

Mathematical modeling provides an additional advantage because treatment resistance and tumor evolution are dynamic processes. Previous mathematical studies have demonstrated that model-based approaches can help characterize tumor dynamics and resistance evolution [11,12]. This suggests that combining mathematical modeling with data-driven deep learning may provide a more comprehensive representation of treatment response.

However, several challenges must be considered. Genomic datasets can contain missing values, batch effects, high dimensionality, and population differences. Deep-learning models may also overfit when the number of features is much larger than the number of patients. In addition, models trained on cancer cell lines may not always translate directly to real-world patient tumors.

Interpretability is another important challenge. Precision oncology requires not only accurate predictions but also understandable biological explanations. Explainable AI approaches can help identify influential genomic features and pathways, but explanations should be biologically validated rather than interpreted as definitive causal mechanisms [19].

Therefore, the proposed framework should be evaluated using independent datasets, appropriate cross-validation, external validation, and where possible, experimental or clinical validation.

**10.Expected Outcomes**

The proposed research is expected to produce:

1. A patient-specific genomic-network representation.
2. A mathematical model for analyzing genomic interactions.
3. A deep-learning model for treatment-response prediction.
4. A framework for predicting drug sensitivity and resistance.
5. Identification of important genomic biomarkers and pathways.

6. An explainable AI component for interpreting predictions.
7. A computational framework supporting personalized cancer therapy.

## 11. Conclusion

The proposed study presents an AI-driven mathematical modeling framework for personalized cancer therapy using genomic networks and deep learning. The framework integrates patient-specific genomic information, biological networks, mathematical modeling, multi-omics analysis, graph-based deep learning, and Explainable AI. Existing research has demonstrated the individual value of genomic profiling, mathematical modeling, deep learning, network analysis, and pharmacogenomic prediction [2–5,10–12,16,17]. However, integrating these components into a unified and interpretable patient-specific framework remains an important research opportunity.

The proposed approach aims to capture both the molecular characteristics of individual tumors and the interactions among genes and biological pathways. By combining these representations with deep learning, the system can potentially improve treatment-response prediction and identify molecular factors associated with therapeutic sensitivity and resistance.

The framework is intended as a research and clinical decision-support approach, not as a replacement for oncologists, clinical trials, or established treatment guidelines. Successful validation using independent patient datasets and prospective clinical studies will be essential before clinical implementation.

**Future Work**

Future work will focus on validating the proposed framework using large-scale and independent cancer datasets. Additional multi-omics data will be incorporated to improve the accuracy of personalized treatment prediction. Advanced Graph Neural Networks and transformer-based models will be explored to capture complex genomic interactions and tumor evolution. Explainable AI techniques will be further enhanced to identify key genes, pathways, and molecular factors influencing treatment response. Finally, prospective clinical validation will be performed to evaluate the reliability, interpretability, and practical usefulness of the framework in precision oncology.

## References

[1] Hanahan, D. (2022). Hallmarks of cancer: New dimensions. *Cancer Discovery*, 12(1), 31–46.
[2] Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., et al. (2013). The Cancer Genome Atlas Pan-Cancer analysis project. *Nature Genetics*, 45(10), 1113–1120.
[3] Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*, 483, 603–607.
[4] Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., et al. (2013). Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. *Nucleic Acids Research*, 41(D1), D955–D961.
[5] Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., et al. (2016). A landscape of pharmacogenomic interactions in cancer. *Cell*, 166(3), 740–754.
[6] Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., et al. (2005). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences*, 102(43), 15545–15550.
[7] Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015). The Molecular Signatures Database Hallmark Gene Set Collection. *Cell Systems*, 1(6), 417–425.
[8] Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., et al. (2019). STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Research*, 47(D1), D607–D613.
[9] Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017). KEGG: New perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Research*, 45(D1), D353–D361.
[10] Zhang, W., Chien, J., Yong, J., & Kuang, R. (2017). Network-based machine learning and graph theory algorithms for precision oncology. *npj Precision Oncology*, 1, 25.
[11] Sun, X., Bao, J., & Shao, Y. (2018). Mathematical modeling and computational prediction of cancer drug resistance. *Briefings in Bioinformatics*, 19(5), 1382–1399.
[12] Yin, A., Moes, D. J. A. R., van Hasselt, J. G. C., Swen, J. J., & Guchelaar, H. J. (2019). A review of mathematical models for tumor dynamics and treatment resistance evolution of solid tumors. *CPT: Pharmacometrics & Systems Pharmacology*, 8(10), 720–737.
[13] LeCun, Y., Bengio, Y., & Hinton, G. (2015). Deep learning. *Nature*, 521, 436–444.
[14] Kipf, T. N., & Welling, M. (2017). Semi-supervised classification with graph convolutional networks. *International Conference on Learning Representations*.

[15] Hamilton, W. L., Ying, R., & Leskovec, J. (2017). Inductive representation learning on large graphs. *Advances in Neural Information Processing Systems*, 30, 1024–1034.
[16] Sharifi-Noghabi, H., Zolotareva, O., Collins, C. C., & Ester, M. (2019). MOLI: Multi-omics late integration with deep neural networks for drug response prediction. *Bioinformatics*, 35(14), i501–i509.
[17] Zhu, J., Wang, J., Wang, X., Gao, M., Guo, B., Gao, M., et al. (2021). Prediction of drug efficacy from transcriptional profiles with deep learning. *Nature Biotechnology*, 39, 1444–1452.
[18] Manica, M., Oskooei, A., Born, J., Subramanian, V., Sáez-Rodríguez, J., & Rodríguez Martínez, M. (2019). Toward explainable anticancer compound sensitivity prediction via multimodal attention-based convolutional encoders. *Molecular Pharmaceutics*, 16(12), 4797–4806.
[19] Gimeno, M., Sada Del Real, K., & Rubio, A. (2023). Precision oncology: A review to assess interpretability in several explainable methods. *Briefings in Bioinformatics*, 24(4), bbad200.
[20] Li, L., Zhao, T., Hu, Y., Ren, S., & Tian, T. (2024). Mathematical modelling and bioinformatics analyses of drug resistance for cancer treatment. *Current Bioinformatics*, 19(3), 211–221.
[21] Veličković, P., Cucurull, G., Casanova, A., Romero, A., Liò, P., & Bengio, Y. (2018). Graph attention networks. *International Conference on Learning Representations*.
[22] Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. *Genome Biology*, 18, 83.
[23] Argelaguet, R., Velten, B., Arnol, D., Dietrich, S., Zenz, T., Marioni, J. C., et al. (2018). Multi-omics factor analysis—A framework for unsupervised integration of multi-omics data. *Molecular Systems Biology*, 14(6), e8124.
[24] Oskooei, A., Born, J., Schoeberl, B., Barenboim, J., & Martínez, M. R. (2019). PaccMann: Prediction of anticancer compound sensitivity with multi-modal attention-based neural networks. *Bioinformatics*, 35(18), 3747–3755.
[25] Zhang, J., Xiong, S., Xu, Y., & Zhang, Y. (2026). Prediction of cancer drug response based on heterogeneous graph neural networks and multi-omics data. *Neural Networks*, 193, 108001.
[26] Gu, G., Han, H., Wu, H., Sun, Y., Liu, P., Jiang, G., et al. (2026). $H^3$CDR: An anti-cancer drug response prediction model driven by heterogeneous and homogeneous hybrid graph neural network. *IEEE Transactions on Computational Biology and Bioinformatics*, 23(1), 284–296.
[27] Lundberg, S. M., & Lee, S.-I. (2017). A unified approach to interpreting model predictions. *Advances in Neural Information Processing Systems*, 30.
[28] Ribeiro, M. T., Singh, S., & Guestrin, C. (2016). "Why should I trust you?": Explaining the predictions of any classifier. *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*, 1135–1144.
[29] Reardon, B., Culhane, A. C., & Van Allen, E. M. (2026). Convergence of machine learning and genomics for precision oncology. *Nature Reviews Cancer*, 26, 217–229.
[30] Li, J., Zhang, L., Yu, Z., Bao, Z., Li, D., et al. (2026). The impact of AI on modern oncology from early detection to personalized cancer treatment. *npj Precision Oncology*, 10, 69.
[31] *The MOGA multi-modal framework based on graph augmentation networks for drug response prediction*. (2026). *iScience*. https://doi.org/10.1016/j.isci.2026.115167.
[32] Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., et al. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature*, 596, 583–589.
[33] Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., et al. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery*, 18, 463–477.
[34] Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine*, 25, 44–56.
[35] Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. *New England Journal of Medicine*, 380, 1347–1358.
[36] Holzinger, A., Biemann, C., Pattichis, C. S., & Kell, D. B. (2017). What do we need to build explainable AI systems for the medical domain? *arXiv preprint arXiv:1712.09923*.
[37] Wu, Z., Pan, S., Chen, F., Long, G., Zhang, C., & Yu, P. S. (2021). A comprehensive survey on graph neural networks. *IEEE Transactions on Neural Networks and Learning Systems*, 32(1), 4–24.
[38] Zhou, J., Cui, G., Hu, S., Zhang, Z., Yang, C., Liu, Z., et al. (2020). Graph neural networks: Foundations, frontiers, and applications. *Proceedings of the IEEE*, 108(11), 209–? [bibliographic details should be verified against the publisher record before final submission].
[39] Indhumathi, M. (2026). *Mathematical Foundations of Explainable Artificial Intelligence*. Stanzaleaf International Journal of Multidisciplinary Studies, 3(1), 1–19.
https://doi.org/10.67313/slijms.2026.36.
[40] Balraj, A., & Karunanithi, J. (2026). *Explicable Artificial Intelligence in Decision-Critical Systems: A Computational and Ethical Perspective*. Stanzaleaf International Journal of Multidisciplinary Studies, 1(1), 8–13. https://doi.org/10.67313/slijms.2026.2

[41] Kanimozhi, J. (2026). *Adaptive Computational Models for Intelligent Data-Driven Decision Systems in Complex Environments*. Stanzaleaf International Journal of Multidisciplinary Studies, 1(1), 14–21. https://doi.org/10.67313/slijms.2026.3.
[42] Pradeepa, S., Rahamtula, S., Sunitha, J., & Agarwal, V. (2026). *Artificial Intelligence and Internet of Things for Sustainable Smart City Development*. Stanzaleaf International Journal of Multidisciplinary Studies, 3(1), 135–150. https://doi.org/10.67313/slijms.2026.45.
[43] Anantharaman, S., & Vishnupriya, V. (2026). *Graph-Theoretic Models for Network Optimization*. Stanzaleaf International Journal of Multidisciplinary Studies, 3(1), 157–171. https://doi.org/10.67313/slijms.2026.47.
[44] Savitha, K., & Kavinkumar, P. (2026). *Artificial Intelligence for Academic Writing Instruction: Innovations in Feedback and Language Development*. Stanzaleaf International Journal of Multidisciplinary Studies, 3(1), 20–31. https://doi.org/10.67313/slijms.2026.37.
[45] Moulieswaran, N., Stephen Samuel, A., & Manoharan, A. (2026). *AI-Powered Digital Pedagogy in English Language Education: A Framework for Twenty-First Century Learning*. Stanzaleaf International Journal of Multidisciplinary Studies**, 3**(1), 60–76. https://doi.org/10.67313/slijms.2026.40